TrialThe oncologist2025

Immune-mediated adverse events in the randomized phase 3 TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer.

Lorenzo Antonuzzo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.